enGene Holdings Inc. (NASDAQ:ENGN) Shares Sold by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC cut its stake in shares of enGene Holdings Inc. (NASDAQ:ENGN) by 56.8% in the 4th quarter, Holdings Channel reports. The firm owned 132,260 shares of the company’s stock after selling 173,774 shares during the quarter. Schonfeld Strategic Advisors LLC’s holdings in enGene were worth $880,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Franklin Resources Inc. increased its stake in shares of enGene by 48.7% in the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after purchasing an additional 389,918 shares during the period. Vontobel Holding Ltd. acquired a new stake in shares of enGene in the fourth quarter valued at $69,000. Finally, Blue Owl Capital Holdings LP lifted its holdings in enGene by 3.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company’s stock valued at $21,014,000 after acquiring an additional 101,006 shares during the last quarter. 64.16% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ENGN. JMP Securities reissued a “market outperform” rating and set a $18.00 price objective on shares of enGene in a research note on Tuesday, April 29th. Morgan Stanley cut their target price on shares of enGene from $37.00 to $34.00 and set an “overweight” rating for the company in a research report on Tuesday, March 11th. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of enGene in a report on Tuesday, March 11th. UBS Group lowered enGene from a “buy” rating to a “neutral” rating and cut their target price for the company from $34.00 to $7.00 in a report on Friday, February 14th. Finally, Piper Sandler started coverage on shares of enGene in a report on Tuesday, February 18th. They set an “overweight” rating and a $26.00 price objective for the company. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $23.29.

enGene Price Performance

Shares of ENGN stock opened at $3.36 on Friday. The company has a market capitalization of $171.28 million, a P/E ratio of -5.79 and a beta of -0.36. enGene Holdings Inc. has a 12 month low of $3.27 and a 12 month high of $14.67. The stock has a 50 day moving average of $4.45 and a two-hundred day moving average of $6.34. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.